Q3 2020 Sales Performance

The changing shape of the respiratory portfolio New portfolio offsetting decline in Advair/Seretide gsk 5,741 6,510 6,991 6,928 6,981 5,227 100% 6% 5% 8% 11% 13% Nucala 15% 23% 32% 30% 33% 28% 39% Ellipta portfolio 23% 16% 7% 32% 25% 7% Advair US 22% 18% 19% 16% Seretide RoW 30% 30% 28% 27% 31% 25% Other 2015 2016 2017 2018 2019 2020 YTD Growth -7% +2% +3% +1% -1% +3% CER Source: GSK results releases 20 20

View entire presentation